Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?

Eur J Gastroenterol Hepatol

aDivision of Pediatric Gastroenterology, Hepatology and Nutrition bDepartment of Pathology, Marmara University School of Medicine, Istanbul cDepartment of Microbiology, Hacettepe University School of Medicine, Ankara, Turkey.

Published: November 2014

Objective: There has been a marked decrease in the eradication rates of Helicobacter pylori infection with standard triple therapy worldwide. Hence, sequential therapy has gained attention as a promising treatment during the last few years. This study was carried out to compare the efficacy of sequential versus standard triple therapy in the context of clarithromycin (CLA) resistance.

Materials And Methods: In this study, children between 3 and 18 years of age, who had documented H. pylori infection, were randomized to receive either standard triple or sequential therapy. H. pylori eradication was ascertained using the C-urea breath test 4-6 weeks after the completion of the treatment. Real-time PCR was performed on gastric biopsy samples for assessment of CLA resistance.

Results: In all, 148 children (median age: 12.18±3.51 years) were recruited randomly into the study. The intention-to-treat eradication rates were 50% (37/74) for the sequential treatment group and 52.7% (39/74) for the standard triple treatment group (P=0.87). A total of 136 children completed the study. The per-protocol eradication rates were 56% (37/66) and 55.7% (39/70) for sequential and standard triple therapy groups, respectively. CLA resistance was assessed and 113 children were included in the final analysis. Of 113 participants, 53 were in the sequential treatment group and 60 were in the standard triple treatment group. The success rates of the respective therapies (29/53=54.7% in sequential, 33/60=55% in standard therapy) were similar (P=0.98). CLA resistance was detected in 29 (25.7%) of the patients. Eradication rates with sequential therapy in CLA susceptible and resistant cases were 60.5% (23/38) and 40% (6/15), respectively (P=0.23). The corresponding figures for the standard triple treatment group were 63% (29/46) and 28.6% (4/14) (P=0.033). Although a higher eradication rate was observed in CLA-resistant cases with sequential therapy, the difference did not reach statistical significance (P=0.69).

Conclusion: In this study, standard triple treatment failed to eradicate H. pylori infection in the majority of the children, and sequential therapy offered only a small advantage over standard triple therapy in the eradication of CLA-resistant strains.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000000190DOI Listing

Publication Analysis

Top Keywords

standard triple
40
sequential therapy
24
triple therapy
20
treatment group
20
eradication rates
16
triple treatment
16
pylori infection
12
sequential
11
standard
11
therapy
11

Similar Publications

Our recently developed approach based on the local coupled-cluster with single, double, and perturbative triple excitation [LCCSD(T)] model gives very efficient means to compute the ideal-gas enthalpies of formation. The expanded uncertainty (95% confidence) of the method is about 3 kJ·mol for medium-sized compounds, comparable to typical experimental measurements. Larger compounds of interest often exhibit many conformations that can significantly differ in intramolecular interactions.

View Article and Find Full Text PDF

Background: Subjective cognitive decline (SCD), in the absence of objective cognitive impairment, may be the first symptomatic manifestation of Alzheimer's disease (AD). Previous studies have suggested that its combination with amyloid-positivity (Aβ+) may represent stage 2 AD, and is associated with a higher risk of future cognitive decline. Here, we aim to (1) confirm this using the plasma Aβ42/40 ratio, and (2) test whether the addition of plasma phospho-tau181 (ptau, a marker of Aβ and tau pathology) could help refine the prediction of future cognitive decline in SCD patients.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, USA.

Background: The spread of tau in Alzheimer's Disease (AD) can be tracked in vivo using [F-18]MK6240, a PET radioligand that binds to tau aggregates in AD with high affinity. However, significant MK6240 signal is also observed in the meninges and sinus and the extra cerebral binding (ECB) signal from these regions can spill into exterior brain regions complicating evaluation of early stage AD tauopathy. This study evaluates the magnitude and variability of ECB in a large imaging cohort to identify trends in this signal.

View Article and Find Full Text PDF

Background: The spread of tau in Alzheimer's Disease (AD) can be tracked in vivo using [F-18]MK6240, a PET radioligand that binds to tau aggregates in AD with high affinity. However, significant MK6240 signal is also observed in the meninges and sinus and the extra cerebral binding (ECB) signal from these regions can spill into exterior brain regions complicating evaluation of early stage AD tauopathy. This study evaluates the magnitude and variability of ECB in a large imaging cohort to identify trends in this signal.

View Article and Find Full Text PDF

Background: The prevalence of dementia in Low and Middle-Income Countries (LMICs), particularly in Latin America and the Caribbean (LAC), is projected to triple by 2050. The Montreal Cognitive Assessment (MoCA) is widely used for cognitive evaluation, but its uniform application in LAC is questionable, especially due to cultural and linguistic diversity of the Spanish-speaking LAC countries.

Method: A systematic literature search was conducted across seven databases, supplemented by a comprehensive review using Google Scholar to identify relevant grey literature.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!